Only Factor V Leiden and prothrombin mutation was documented for the systemic VTE patients in MATS, whereas a full thrombophilia panel with eight tests including JAK2 mutation [7] was available for 74% in the MVT cohort. This evidence concerns the gene JAK2 and thrombophilia.